Sentiment Trading

Inmune Bio Inc. reported its first quarter 2025 results, with a focus on advancing its pipeline of cancer therapies and a market capitalization of approximately $173.53 million.

Inmune Bio Inc. is set to release its Q1 2025 earnings, a critical moment for the biotech company as investors and stakeholders await signs of progress in its pipeline and potential for market success.